Dyskinesia Matters |
| |
| Authors: | M. Angela Cenci MD PhD Sara Riggare MSci Rajesh Pahwa MD David Eidelberg MD Robert A. Hauser MD |
| |
| Affiliation: | 1. Basal Ganglia Pathophysiology Unit, Dept. of Experimental Medical Science, Lund University, Lund, Sweden;2. Department for Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden;3. University of Kansas Medical Center, Movement Disorders Division, Kansas City, Kansas, USA;4. Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA;5. University of South Florida, Department of Neurology, Tampa, Florida, USA |
| |
| Abstract: | ![]()
Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued. © 2019 International Parkinson and Movement Disorder Society |
| |
| Keywords: | animal models basal ganglia drug development pathophysiology therapy complications |
|
|
